Volume | 2,821 |
|
|||||
News | - | ||||||
Day High | 8.8799 | Low High |
|||||
Day Low | 8.1312 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Oncternal Therapeutics Inc | ONCT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
8.80 | 8.1312 | 8.8799 | 8.60 | 8.95 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
75 | 2,821 | $ 8.66 | $ 24,434 | - | 5.5656 - 13.14 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:00:00 | 285 | $ 8.60 | USD |
Oncternal Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
25.45M | 2.96M | - | 785k | -39.48M | -13.34 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Oncternal Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ONCT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 9.00 | 9.48 | 8.1312 | 8.96 | 7,277 | -0.40 | -4.44% |
1 Month | 8.19 | 9.852 | 7.81 | 8.77 | 7,459 | 0.41 | 5.01% |
3 Months | 9.00 | 10.613 | 7.4819 | 9.12 | 9,237 | -0.40 | -4.44% |
6 Months | 6.58 | 13.14 | 5.5656 | 8.40 | 138,118 | 2.02 | 30.70% |
1 Year | 7.102 | 13.14 | 5.5656 | 7.47 | 182,665 | 1.50 | 21.09% |
3 Years | 128.00 | 137.798 | 5.22 | 48.26 | 476,144 | -119.40 | -93.28% |
5 Years | 137.40 | 211.20 | 5.22 | 75.80 | 664,708 | -128.80 | -93.74% |
Oncternal Therapeutics Description
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. |